Disc Medicine Announces Presentations at ASH Annual Meeting
The company said two oral presentations will feature additional data from its RALLY-MF Phase 2 trial of selcodebart.
The company said two oral presentations will feature additional data from its RALLY-MF Phase 2 trial of selcodebart.